Kidney Function During and After Withdrawal of Long-Term Irbesartan Treatment in Patients With Type 2 Diabetes and Microalbuminuria
Response to Andersen, Bröchner-Mortensen, and Parving
- Thomas Kaiser12,
- Christiane Florack1 and
- Peter T. Sawicki, MD, PHD12
- 1DIeM, Institute for Evidence-Based Medicine, Cologne, Germany
- 2Department of Internal Medicine, St. Franziskus Hospital, Cologne, Germany
- Address correspondence to T. Kaiser, DIeM, Institute for Evidence-Based Medicine, Venloer Str. 301-303, D-50823 Cologne, Germany. E-mail: t.kaiser{at}di-em.de
Response to Andersen, Bröchner-Mortensen, and Parving
We read with great interest the article by Andersen, Bröchner-Mortensen, and Parving (1) about the effects of long-term treatment with irbesartan on kidney function in a subgroup of the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study (IRMA)-2 trial (2). In this population, the authors did not find a significant difference between …
In this Issue
June 2004, 27(6)
Kidney Function During and After Withdrawal of Long-Term Irbesartan Treatment in Patients With Type 2 Diabetes and Microalbuminuria
